Get the Stockscreener App
2.72
7.51%
0.19
After Hours:
2.73
0.010
+0.37%
Esperion Therapeutics Inc stock is traded at $2.72, with a volume of 7.20M.
It is up +7.51% in the last 24 hours and down -4.23% over the past month.
Esperion Therapeutics Inc is a pharmaceutical company. It specializes in developing and commercializing accessible, oral, once-daily, non-statin medicines for patients struggling with elevated low-density lipoprotein cholesterol. The firm has the business of researching, developing and commercializing therapies for the treatment of patients with the elevated low-density lipoprotein cholesterol operating segment. Its products include NEXLETOL, NEXLIZET, NILEMDO and NUSTENDI. The company manages its business in one operating segment, which is the business of researching, developing and commercializing therapies for the treatment of patients with elevated LDL-C.
See More
Previous Close:
$2.53
Open:
$2.55
24h Volume:
7.20M
Relative Volume:
1.09
Market Cap:
$548.41M
Revenue:
$116.33M
Net Income/Loss:
$-209.25M
P/E Ratio:
-1.283
EPS:
-2.12
Net Cash Flow:
$-135.49M
1W Performance:
-12.82%
1M Performance:
-4.23%
6M Performance:
+166.67%
1Y Performance:
+38.07%
1-Day Range:
$2.54
$2.745
1-Week Range:
$2.30
$3.16
52-Week Range:
$0.6925
$3.94
Esperion Therapeutics Inc Stock (ESPR) Company Profile
Name
Esperion Therapeutics Inc
Sector
Phone
734-887-3903
Address
3891 RANCHERO DRIVE, SUITE 150, ANN ARBOR, MI
Compare ESPR with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
ESPR
Esperion Therapeutics Inc
|
2.72 | 586.01M | 116.33M | -209.25M | -135.49M | -2.12 |
|
ZTS
Zoetis Inc
|
142.26 | 62.54B | 9.39B | 2.62B | 2.22B | 5.8121 |
|
TAK
Takeda Pharmaceutical Co Adr
|
13.72 | 43.30B | 29.96B | 957.25M | 4.77B | 0.2956 |
|
HLN
Haleon Plc Adr
|
9.08 | 40.08B | 14.26B | 1.98B | 2.47B | 0.4327 |
|
TEVA
Teva Pharmaceutical Industries Ltd Adr
|
20.02 | 22.98B | 16.70B | -157.13M | 1.19B | -0.1446 |
|
UTHR
United Therapeutics Corp
|
440.06 | 19.90B | 3.08B | 1.24B | 1.07B | 25.61 |
Esperion Therapeutics Inc Stock (ESPR) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Dec-18-24 | Initiated | Goldman | Neutral |
| Dec-17-24 | Initiated | Cantor Fitzgerald | Overweight |
| Jun-20-24 | Downgrade | BofA Securities | Neutral → Underperform |
| Jan-03-24 | Downgrade | BofA Securities | Buy → Neutral |
| Nov-20-23 | Resumed | JP Morgan | Neutral |
| Aug-01-23 | Upgrade | Northland Capital | Under Perform → Market Perform |
| Jun-15-23 | Upgrade | BofA Securities | Underperform → Buy |
| Mar-16-23 | Downgrade | BofA Securities | Neutral → Underperform |
| Mar-16-23 | Downgrade | Northland Capital | Market Perform → Under Perform |
| Mar-07-23 | Upgrade | Credit Suisse | Underperform → Neutral |
| Feb-27-23 | Resumed | BofA Securities | Neutral |
| Feb-24-23 | Upgrade | Jefferies | Hold → Buy |
| Feb-03-23 | Upgrade | Morgan Stanley | Underweight → Equal-Weight |
| Aug-03-22 | Downgrade | Credit Suisse | Neutral → Underperform |
| May-05-22 | Upgrade | JP Morgan | Underweight → Neutral |
| Mar-10-22 | Initiated | H.C. Wainwright | Buy |
| Oct-19-21 | Downgrade | Credit Suisse | Outperform → Neutral |
| Oct-14-21 | Downgrade | Morgan Stanley | Equal-Weight → Underweight |
| May-05-21 | Downgrade | Stifel | Buy → Hold |
| Apr-26-21 | Resumed | Credit Suisse | Outperform |
| Mar-11-21 | Initiated | Morgan Stanley | Equal-Weight |
| Feb-12-21 | Downgrade | Jefferies | Buy → Hold |
| Feb-09-21 | Downgrade | Goldman | Neutral → Sell |
| Jan-15-21 | Downgrade | BofA Securities | Buy → Neutral |
| Nov-10-20 | Upgrade | Credit Suisse | Neutral → Outperform |
| Sep-29-20 | Resumed | JP Morgan | Underweight |
| Aug-11-20 | Downgrade | Credit Suisse | Outperform → Neutral |
| Apr-01-20 | Resumed | BofA/Merrill | Buy |
| Mar-17-20 | Upgrade | Citigroup | Neutral → Buy |
| Feb-24-20 | Downgrade | Northland Capital | Outperform → Market Perform |
| Feb-14-20 | Downgrade | Citigroup | Buy → Neutral |
| Sep-16-19 | Upgrade | Goldman | Sell → Neutral |
| May-29-19 | Downgrade | Goldman | Neutral → Sell |
| May-06-19 | Upgrade | BofA/Merrill | Underperform → Neutral |
| Apr-26-19 | Upgrade | Goldman | Sell → Neutral |
| Mar-13-19 | Upgrade | JP Morgan | Underweight → Neutral |
| Jan-07-19 | Reiterated | Needham | Strong Buy |
| Dec-13-18 | Initiated | Goldman | Sell |
| Oct-29-18 | Upgrade | Northland Capital | Market Perform → Outperform |
| Oct-16-18 | Initiated | BTIG Research | Buy |
| Aug-17-18 | Upgrade | Citigroup | Neutral → Buy |
| Jul-11-18 | Downgrade | Northland Capital | Outperform → Market Perform |
| May-03-18 | Downgrade | JP Morgan | Neutral → Underweight |
| May-02-18 | Downgrade | BofA/Merrill | Buy → Underperform |
View All
Esperion Therapeutics Inc Stock (ESPR) Latest News
Esperion Therapeutics Inc Stock Analysis and ForecastRelative Strength Index (RSI) & Free Long-Term Investment Planning - earlytimes.in
Published on: 2025-10-13 10:12:04 - newser.com
Will Esperion Therapeutics Inc. stock gain from lower inflationTreasury Yields & Weekly Market Pulse Updates - newser.com
What’s the recovery path for long term holders of Esperion Therapeutics Inc.Treasury Yields & Weekly Market Pulse Updates - newser.com
Can Esperion Therapeutics Inc. stock reach $100 price targetEarnings Beat & AI Enhanced Trading Signals - newser.com
Why Esperion Therapeutics Inc. stock is favored by top institutions2025 Short Interest & Daily Profit Focused Screening - newser.com
How to use a screener to detect Esperion Therapeutics Inc. breakoutsWeekly Market Report & Long Hold Capital Preservation Tips - newser.com
How strong is Esperion Therapeutics Inc. stock balance sheet2025 Institutional Moves & Fast Exit and Entry Strategy Plans - newser.com
Why Esperion Therapeutics Inc. is moving todayTrade Analysis Summary & Short-Term High Return Strategies - newser.com
Esperion Therapeutics Inc. (ESPR) Stock Price | Live Quotes & Charts | NSD - StocksToTrade
Esperion Therapeutics (ESPR): Assessing Valuation After $75 Million Discounted Stock Offering and Share Price Drop - Yahoo Finance
Will Esperion Therapeutics Inc. stock benefit from upcoming earnings reportsJuly 2025 Fed Impact & Advanced Technical Analysis Signals - newser.com
Why Esperion Therapeutics (ESPR) Is Up After $75M Equity Raise and Generic Settlement News - Yahoo Finance
How currency fluctuations impact Esperion Therapeutics Inc. stockTake Profit & Fast Momentum Entry Tips - newser.com
Why Is Esperion Therapeutics Stock Sinking Premarket Today? - Stocktwits
Is Esperion Therapeutics Inc. stock attractive for hedge fundsJuly 2025 Selloffs & Safe Entry Point Identification - newser.com
ESPR- Japanese Drug Approval, Otsuka Payments to Help this Biotech Play - Yahoo Finance
(10/10/25) ESPR: Japanese Drug Approval, Otsuka Payments to Help this Biote - moneyshow.com
ESPR Stock Drops 17% on Pricing of $75M Common Stock Offering - sharewise.com
Is Esperion Therapeutics Inc. stock a buy on dips2025 Trading Volume Trends & Safe Entry Trade Reports - newser.com
Published on: 2025-10-09 02:49:28 - newser.com
Esperion Therapeutics (NASDAQ:ESPR) Earns Sell (D-) Rating from Weiss Ratings - MarketBeat
Esperion Announces Public Offering to Raise $70.2 Million - TipRanks
Esperion Therapeutics Down Over 15%, on Pace for Largest Percent Decrease Since December 2024 -- Data Talk - 富途牛牛
Esperion Therapeutics (NASDAQ:ESPR) Shares Gap DownShould You Sell? - MarketBeat
Esperion Therapeutics’ Bold Move: Stock Offering at $2.50 - StocksToTrade
Esperion Therapeutics prices $75M public offering - MSN
Penguin Solutions Posts Q4 Earnings, Joins Esperion Therapeutics, Joby Aviation And Other Big Stocks Moving Lower In Wednesday's Pre-Market Session - Benzinga
Esperion Therapeutics Prices $75 Million Share Offering - MarketScreener
Esperion prices $75 million public offering of common stock By Investing.com - Investing.com Nigeria
Esperion Announces Pricing of Public Offering of Common Stock - The Manila Times
Esperion prices public offering of 30 million shares at $2.50 each - MarketScreener
Esperion Therapeutics Announces Pricing of $75 Million Public Offering of Common Stock - Quiver Quantitative
Esperion prices $75 million public offering of common stock - Investing.com India
$75M Raise — Esperion Prices 30M Shares to Fund Oral LDL‑C Program - Stock Titan
Esperion Therapeutics Experiences Evaluation Revision Amidst Mixed Market Indicators and Performance Trends - Markets Mojo
Esperion announces proposed public offering of common stock - MarketScreener
ESPR Settles Nexletol/Nexlizet Patent Litigation With RDY, Stock Up - MSN
Esperion launches public offering of common stock to raise capital By Investing.com - Investing.com Canada
Esperion Therapeutics tumbles after stock offering launch - TradingView
Esperion Announces Strategic Expansion Plans for Bempedoic Acid - TipRanks
Esperion launches public offering of common stock to raise capital - Investing.com
Esperion launches proposed public offering of common stock; shares fall 21% (ESPR:NASDAQ) - Seeking Alpha
Esperion stock tumbles after announcing public offering - Investing.com
Esperion Announces Proposed Public Offering of Common Stock - Benzinga
15% Overallotment Option: Esperion Commences Underwritten Public Offering of Common Stock on SEC Shelf - Stock Titan
Will Esperion Therapeutics Inc. outperform the marketMarket Activity Recap & Stepwise Entry and Exit Trade Signals - newser.com
Will Esperion Therapeutics Inc. rebound enough to break evenRate Hike & Low Risk Entry Point Tips - newser.com
Esperion Therapeutics Inc Stock (ESPR) Financials Data
Revenue
Net Income
Cash Flow
EPS
Esperion Therapeutics Inc Stock (ESPR) Insider Trading
| Insider Trading | Relationship | Date | Transaction | Cost | #Shares | Value ($) | #Shares Total |
|---|---|---|---|---|---|---|---|
| Koenig Sheldon L. | President and CEO |
Sep 17 '25 |
Sale |
2.79 |
28,427 |
79,254 |
1,518,831 |
| Halladay Benjamin | Chief Financial Officer |
Sep 17 '25 |
Sale |
2.81 |
7,046 |
19,785 |
474,862 |
1.42%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):